Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Now Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Wall Street consensus is “Moderate Buy”: Seven analysts rate Tarsus Pharmaceuticals a buy, one a strong buy, one a hold and one a sell. The average 12-month price target is $100.86 versus the reported share price of $73.00.
• Quarterly results were mixed: Revenue of $173.91 million exceeded estimates, but adjusted EPS of negative $0.43 missed the consensus estimate of negative $0.19. Analysts expect a full-year loss of approximately $4.25 per share.
• Insiders have been selling shares: Executives sold 48,031 shares worth about $4.0 million over the past 90 days, while institutional investors own approximately 90.01% of the stock.

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $100.86.

TARS has been the topic of several analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Mizuho reduced their price objective on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating on the stock in a research note on Friday, July 31st. Jefferies Financial Group boosted their price target on Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the company a "buy" rating in a report on Tuesday, September 8th. The Goldman Sachs Group assumed coverage on Tarsus Pharmaceuticals in a research report on Thursday, September 24th. They issued a "buy" rating and a $116.00 price objective for the company. Finally, Wall Street Zen lowered Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $73.00 on Monday. The company has a quick ratio of 3.17, a current ratio of 3.20 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $3.20 billion, a P/E ratio of -66.97 and a beta of 0.44. Tarsus Pharmaceuticals has a 52-week low of $53.89 and a 52-week high of $91.53. The stock's fifty day simple moving average is $73.07 and its 200-day simple moving average is $67.00.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The company had revenue of $173.91 million for the quarter, compared to analysts' expectations of $169.65 million. As a group, equities research analysts forecast that Tarsus Pharmaceuticals will post -4.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, CEO Bobak Azamian sold 10,000 shares of Tarsus Pharmaceuticals stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $90.56, for a total value of $905,600.00. Following the completion of the sale, the chief executive officer owned 827,991 shares in the company, valued at $74,982,864.96. The trade was a 1.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Lin sold 3,180 shares of the company's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $87.50, for a total transaction of $278,250.00. Following the transaction, the insider directly owned 1,590 shares of the company's stock, valued at approximately $139,125. This represents a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 48,031 shares of company stock valued at $4,004,227. Insiders own 9.64% of the company's stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Parallel Advisors LLC increased its position in Tarsus Pharmaceuticals by 139.2% during the first quarter. Parallel Advisors LLC now owns 500 shares of the company's stock worth $35,000 after purchasing an additional 291 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Tarsus Pharmaceuticals by 367.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company's stock valued at $50,000 after purchasing an additional 558 shares during the last quarter. Rockefeller Capital Management L.P. grew its stake in shares of Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company's stock valued at $105,000 after buying an additional 172 shares during the period. State of Wyoming purchased a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $103,000. Finally, Nykredit A S purchased a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $106,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company concentrates on areas of significant unmet need in ophthalmology and aims to address conditions that can affect ocular health, comfort and vision.

Tarsus' primary product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.